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Creation of new biocompatible nanomaterials, which can exhibit the specific biological effects, is an 
important complex problem that requires the use of last accomplishments of biotechnology. The effect of pristine 
water-soluble fullerene C60 on ATPase activity and superprecipitation reaction of rabbit skeletal muscle natural 
actomyosin has been revealed, namely an increase of actomyosin superprecipitation and Ìg2+, Ñà2+- and K+-
ATPase activity by fullerene was investigated. We conclude that this finding offers a real possibility for the 
regulation of contraction-relaxation of skeletal muscle with fullerene C60. 
K e y  w o r d s: fullerene C60, skeletal muscle natural actomyosin, ATPase activity, superprecipitation, atomic 
force microscopy, molecular docking. 
The purposeful application of biocompatib-le low toxic nanomaterials (no more than 100 nm in dimensions) is a relevant prob-
lem in modern nanobiotechnologies. It is assumed 
that the use of nanoparticles will help to solve the 
problems of early disease diagnostics and targeted 
delivery of drugs into tissues and cells, as well as 
new methods of selective therapies. Among other 
possible effective therapeutic agents a prominent 
position belongs to the fullerene C60 [1]. We know 
that it normalizes cellular metabolism and neu-
ral processes, increasing resistance to stress, ex-
hibits antiviral properties, has a pronounced anti-
inflammatory and anti-allergic action, enhances 
the activity of enzymes and regenerative capacity 
of tissues [2]. Finally, fullerene C60 and its deriva-
tives can be an aid in the treatment of cancer by 
improving the functions of the immune and anti-
oxidant systems [3–5]. 
Fullerene C60 is hydrophobic – it is insolu-
ble in polar solvents, which limit its bioavailability 
[6]. In order to increase its hydrophilic properties 
the C60 molecule was widely modified (chemical 
functionalization) [7]. Aqueous solution of pristine 
(unmodified) fullerene C60 (C60FAS) has been re-
ceived by the transferring of molecules C60 from 
toluene in water with following sonication [8]. It 
was found that the dark brown solution is a typical 
colloidal system containing a single molecule C60 
and spherical clusters with a diameter of 2-3 nm or 
more (depending on the concentration of fullere-
nes C60 in water) in hydrated state [9]. The most 
energetically favorable structure in this aqueous 
solution is clathrate C60(H2O)60 [8].
Due to the nanodimension the pristine water-
soluble fullerene C60 can penetrate the cell mem-
brane [10]. 
Toxicity is a major concern in using fullerene-
containing materials for biomedical applications 
since fullerenes can undoubtedly have toxic effects 
on human cells and animals [11]. It is important to 
note that used Ñ60FAS does not show a toxic effect 
with respect to rat erythrocyte and thymocyte cells 
at concentrations below 0.1 mg/ml within 24 h of 
incubation [12, 13]. 
Despite the large number of the studies on the 
interaction of fullerene C60 with biological objects 
in vitro and in vivo, almost no information on their 
impact on the functional properties of muscles were 
reported. Only one investigation shows changes 
in physiological and biochemical processes in the 
muscles under the influence of fullerene C60 and its 
derivatives. So, it was found that the fullerene de-
rivative monomalonic acid C60 (10
-5 M) inhibited 
the endothelium-dependent relaxation induced 
by acetylcholine but did not affect the agonist-
induced contractile response of aortic smooth 
muscle of rabbit [14]. Fullerenol (polyhydroxylated 
derivative of fullerene C60) inhibits the prolifera-
tive responses in a number of cells, including rat 
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aortic and human coronary artery smooth muscle 
cells in a concentration dependent manner [15]. 
Fullerene-based nanocationic particles (porphyrin 
adducts of cyclohexyl fullerene C60) were described 
to treat hypoxia-induced mitochondrial dysfunc-
tion in the mammalian heart muscle [16]. Electron 
microscopy demonstrated the ability of complexes 
of C60 with polyvinylpyrrolidone not to prevent the 
formation of actin filaments, and not to destroy 
them in vitro [17]. Finally, fullerenol nanoparti-
cles have been validated as potential candidates for 
the creation of artificial muscles because of their 
excellent proton conductivity, hydrophilicity and 
biocompatibility [18]. But the mechanisms of na-
nostructure’s action on muscle are still not clear. 
The ATPase reaction is the main driving force 
behind the process of muscle contraction as its 
chemical stage [19]. The activity in the presence of 
small concentrations (mM) of Mg2+ and enhanced 
by concentrations of Ca2+ of several mM is referred 
to as Mg2+,Ca2+-ATPase. This activity is important 
considering the physiological conditions in muscle 
cells. The activity in the presence of EGTA (ab-
sence of divalent cations) and high concentrations 
of KCl is referred to as K+(EGTA)-ATPase. 
It was found that fullerenol influences the 
membrane ATPase, namely, decreases the activi-
ty of Na+,K+-ATPase as well as Mg2+,Ca2+-ATPase 
and, thus, may modulate ion transport across 
membranes [20]. However, the effect of fullerene 
C60 on the actomyosin ATPase activity, which is 
crucial to the contractile mechanism, is not es-
tablished. 
There is no uncertainty that the ATPase ac-
tivity underlies the contractile processes of the ac-
tomyosin system, but it is noticed that not all the 
actomyosin ATPase activity is expressed as con-
traction [21]. The superprecipitation of actomyosin 
is generally accepted to be basically the phenom-
enon of skeletal muscle contraction in vitro [22]. 
The superprecipitation reaction can be considered 
as a simplified model of muscle contraction. 
Thus, the aim of this investigation was to 
measure the effect of fullerene C60 in different 
concentrations on ATPase activity and superpre-
cipitation of rabbit skeletal muscle actomyosin.
Materials and Methods
Material preparation and characterization. The 
highly stable Ñ60FAS with a maximum concentra-
tion of 0.1 mg/ml was prepared according to the 
procedure [8]. 
The state of fullerene C60 in aqueous solu-
tion was monitored using an atomic force micros-
copy (AFM) technique («Solver Pro M» system; 
NT-MDT, Russia). Samples were deposited onto 
cleaved mica substrates by precipitation from an 
aqueous solution droplet. AFM measurements 
were performed after complete evaporation of the 
solvent. Sample visualization was carried out in a 
semicontact (tapping) mode. NSG10 (NT-MDT) 
probes were used. 
The RCSB PDB database was used as a tem-
plate to construct a three-dimensional model of 
skeletal muscle actomyosine complex (actin-1atn 
[23]; myosin-1mmg [24]). The actin and myo-
sin were «stitched» into a single complex using 
a Chimera software package (NIGMS, USA). 
Molecular docking (MD) on the affinity of 
actomyosin+fullerene C60 system was performed 
with software package flo+ [25].
Contraction of skeletal muscle is based on 
the interaction of the myosin head (S1) with actin, 
and is powered by the coupled hydrolysis of ATP. 
Natural actomyosin was prepared from rabbit (So-
viet Chinchilla) skeletal muscle using the method 
suggested by Perry and Corsi [26]. Protein con-
centration was determined by the biuret reaction, 
bovine serum albumin being taken as a standard. 
Natural actomyosin contains the principal protein 
components such as actin, myosin, and troponin/
tropomyosin for the muscle contractile system. 
Composition of proteins was controlled by electro-
phoresis [27]. 
The animals used in this study were treated 
in accordance with international principles of the 
European Convention for the protection of verte-
brate animals used for experimental and other sci-
entific purposes (Strasbourg, 1986).
Measurement of ATPase activity. To evaluate 
the effect of fullerene C60 on actomyosin complex 
the activity of ATPase of native actomyosin (as a 
control) in the presence of magnesium and calci-
um (Mg2+,Ñà2+-ATPase activity or actin-activating 
ATPase) and in the presence of chelator of Ñà2+ 
ions – EGTA (Ê+-ATPase activity or actin-relax-
ing ATPase) was measured. Changes of ATPase 
activity of protein complexes in the presence of 
various fullerene C60 concentrations (in the range 
from 10-3 to 10-7 mg/ml) were measured. 
The reaction mixture for Mg2+,Ñà2+-ATPase 
as well as for K+-ATPase at 37 °C consisted of 
0.28 mg/ml of actomyosin, 50 mM KCl, 20 mM 
imidasole buffer (pH 7.5), 2.5 mM MgCl2 and 
0.1 mM CaCl2. Moreover, 1 mM EGTA was 
added under the K+-ATPase activity of actomyosin 
study. Under these conditions ATPase activity of 
actomyo sin was determined by measuring hydro-
lyzed Pi. The reaction was started by the addition 
of 1 mM ATP and stopped by the addition of an 
equal volu me of cold 10% TCA. The amount of Pi 
liberated during the 5 min incubation was deter-
mined according to the method suggested by Fiske 
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and Subbarow [26]. ATPase activity was expressed 
in nmol Pi min
-1⋅mg-1 protein.
All chemicals used in this study were pur-
chased from Sigma (Germany). 
Measurement of superprecipitation reaction. 
The superprecipitation was examined using the 
method suggested by Ohizumi [26]. The super-
precipitation was carried out in a medium which 
contained 0.2 mg/ml of natural actomyosin, 1 mM 
CaCl2, 1 mM MgCl2, 50 mM KCl, 0.1 mM EGTA 
and 20 mM Tris⋅HCl at pH 7.5 and 25 °C, and the 
change in the absorbance at 450 nm was measured. 
Fullerene C60 was added to incubation medium be-
fore 1 mM ATP, which initiates a superprecipita-
tion reaction. 
Registration of kinetic curves of superprecipi-
tation of actomyosin was set out on spectropho-
tometer (SPECORD M40, Germany). From the 
obtained kinetic curves, the value of superprecipi-
tation was calculated by the formula (Àmax(450)–À0), 
where À0 and Àmax(450) are the values of the initial 
and maximum absorbtion of actomyosin, respec-
tively, during the superprecipitation reaction. Ab-
solute error in the measurement of the absorbtion 
was ± 0.004.
The kinetic Burdyga-Kosterin method [28] 
was used for the analysis of the results. It allows 
one to calculate the normalized maximum speed 
(Vn) of superprecipitation reaction
,           (1)
where n is a slope (steepness) coefficient of super-
precipitation curve; τ is a characteristic time that is 
necessary to achieve the half of the maximum val-
ue of superprecipitation - 1/2(Àmax(450)–À0). These 
kinetic parameters are from the experiment.
Changes of superprecipitation reaction value 
in the presence of fullerene C60 at concentrations 
from 10-3 to 10-7 mg/ml were measured. 
Statistics. Statistical analysis was performed 
by conventional methods of variation statistics [29]. 
Validity of the difference between the control and 
experimental measurements was estimated within 
the Student’s t-test using Origin 8.0 software 
(OriginLab Corporation, USA). The differen ce 
between the compared values was considered valid 
at P < 0.05. 
Results and Discussion
The AFM picture in Fig. 1, which corre-
sponds to the initial concentration of fullerene 
C60 in aqueous solution (0.1 mg/ml), demonstrates 
both the individual molecules of C60 with diameter 
Fig. 1. AFM image of fullerene C60 aqueous solution 
with concentration 0.1 mg/ml on mica (tapping mode)





0.8 ± 0.2 nm as well as their clusters with size 
1.5-2 nm, that is in a good agreement with our 
theoretical calculations and neutron spectroscopic 
data [8, 9]. In AFM image the presence of indi-
vidual fullerene C60 aggregates with size 10-100 nm 
was seen too. 
In this regard it is necessary to note the effect 
of ionic strength of the medium on the structural 
organization of fullerene Ñ60 that is important 
for the clarification of the mechanisms of their 
specific biological action. So, in paper [30] it was 
shown that fullerene C60 in various physiological 
solutions forms close-packed islands in the thick-
ness of a monolayer and significantly affects the 
processes of growth of salt crystals.
MD demonstrates the binding of fullerene C60 
with actomyosin complex in the active site of myo-
sin (Fig. 2). The calculated energy parameters for 
the actomyosin+fullerene C60 system are shown in 
Table. Compared with the model of actomyosin 
binding with ATP, the studied model of fullere-
ne C60 binding does not presume the formation 
of hydrogen bonds. The calculations of the con-
tact ener gy indicate that fullerene C60 well closes 
the active site of actomyosin complex, filling the 
pocket and holding there. However, the energy of 
van der Waals interactions between the ligand and 
the protein shows a significant steric perturbation, 
which can neutralize positive contribution to en-
ergy of ligand retention. Therefore, the MD results 
show the possibility of fullerene C60 binding in 
the active center of actomyosin, with a temperate 
strength. 
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The above MD calculation assumed that ac-
tomyosin mainly interacts with a single fullere-
ne C60, and interaction of the fullerene cluster 
(aggregate) with an active center of actomyosin is 
unlikely.
The obtained results of impacting fullere-
ne C60 on the actomyosin ATPase activity are 
presented in Fig. 3. Fullerene C60 in a low con-
centration of 10-7 mg/ml does not affect the 
Mg2+,Ñà2+-ATPase activity of actomyosin, but in-
hibit Ê+-ATPase activity by 29%. Fullerene C60 in 
concentration of 10-5 mg/ml caused the increasing 
in Mg2+,Ñà2+-ATPase activity by 19% compared 
with the control value. Ê+-ATPase activity of ac-
tomyosin also was elevated by 15% under above 
concentration of fullerene C60. The influence of 
fullerene C60 in concentration of 10
-3 mg/ml on 
Mg2+,Ñà2+-ATPase and Ê+-ATPase activity was of 
the similar character: Mg2+,Ñà2+-ATPase activity 
Fig. 2. MD calculated binding model of fullerene C60 with active site of myosin
Energy parameters of actomyosin + fullerene C60 and actomyosin + ATP (for comparison) systems
Energy/Investigated system Actomyosin + fullerene C60, kJ Actomyosin + ATP, kJ
Free energy 50.0 -17.3
Contact energy -94.0 -97.0
Hydrogen bonds 0 17.0
Energy of van der Waals interactions 
between ligand and protein
63.5 11.1
Internal stress in the ligand 34.9 23.7
increased by 29%, and Ê+-ATPase activity – by 
35%. Note that Mg2+,Ñà2+-ATPase and Ê+-ATPase 
activities were 152.98 and 64.21 nmol Pi⋅min
-1⋅mg-1, 
respectively, in the control.
In this context, one has to mention that if 
actomyosin in a dilute solution (10-7 mg/ml) prefe-
rentially interacts with a single fullerene C60, with 
the concentration increasing to 10-3 mg/ml the in-
teraction with a small fullerene C60 aggregate may 
be predominant, that leads to a more pronounced 
(see Fig. 3, a), or even opposite (see Fig. 3, b) 
effect of fullerene C60 on the ATPase activity of 
actomyosin.
Fig. 4 shows the actomyosin superprecipita-
tion reaction recorded under the fullerene C60 ac-
tion. The results show that the characteristics of su-
perprecipitation reaction were increased depending 
on the used concentration of fullerene C60: in the 
presence of 10-7 mg/ml of fullerene C60 the value 
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Fig. 3. Mg2+,Ca2+-ATPase (a) and Ê+-ATPase (b) activity of actomyosin under the different concentration of 
fullerene C60 (M ± m, n = 9; *significant differences compared with a control (ATPase reaction without fullerene 







































of superprecipitation enhanced from 0.115 ± 0.002 
unities in the control to 0.135 ± 0.002 unities. The 
time that is necessary to achieve the half maxi-
mum value of superprecipitation did not change 
relative to the control value and was 5.6 min. 
For the fullerene C60 concentrations of 10
-5 and 
10-3 mg/ml this parameter increased and reached 
6.0 and 7.0 min, respectively. For a concentra-
tion of 10-5 mg/ml the value of superprecipita-
tion also increased relative to the control and was 
0.144 ± 0.002 unities. The greatest value of super-
precipitation of 0.180 ± 0.001 unities was observed 
in the presence of 10-3 mg/ml of fullerene C60. 
For more information the maximum normali-
zed rate of superprecipitation reaction was calcu-
lated by the formula (1). As shown in Fig. 5, at the 
fullerene C60 concentration of 10
-7 mg/ml, there 
was a slight increase in normalized maximum rate 
by 4.7% compared with the control, the value of 
which was taken as 100%. For higher concentra-
tions of fullerene C60, 10
-5 and 10-3 mg/ml, the 
value of the normalized maximum rate decreased 
by 5.5% and 12.2%, respectively, relative to the 
control. 
Thus, fullerene C60 showed dose-dependent 
effect, which may be due to the formation of ag-
gregates (clusters) with increasing concentration in 
the sample [8-9].
It is known [31–33] that a common feature 
of the most muscles diseases (progressive muscu-
Fig. 4. Typical kinetic curves of rabbit skeletal muscle 
actomyosin superprecipitation under the different 
concentration of fullerene C60: 1 – native actomyosin 
(control); 2 – 10-7; 3 – 10-5 and 4 – 10-3 mg/ml
t, min



















Fig. 5. Normalized maximum speed (Vn) of 
superprecipitation reaction (in % compared with 
control taken as 100%) of rabbit skeletal muscle 
natural actomyosin under the different concentration of 
fullerene C60 (M ± m, n = 10; *significant differences 
compared with a control (superprecipitation reaction 
without fullerene C60 ) at P < 0.05)
Control
Concentration, mg/ml
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lar dystrophy, muscle atrophy, inflammatory myo-
pathy including myositis and polymyositis, etc.), 
which are accompanied by muscle weakness (e.g., 
chronic muscle fatigue), is a decline of muscle 
myo fibril protein content. The fall in the ATPase 
activity of myosin can be also observed in the mus-
cle pathology. On this basis the fact of superprecip-
itation reaction and ATPase activity of actomyosin 
promotion by fullerene C60 can be promising for 
further research.  
Thus, we conclude that pristine water-soluble 
fullerene C60 effects the function of the actomyo-
sin complex, namely, with increasing fullerene 
concentration (10-5–10-3 mg/ml) the fullerene C60 
reliably activates the ATPase activity and the su-
perprecipitation reaction of rabbit skeletal muscle 
actomyosin. This may be due to the binding of 
fullerene C60 with aminoacid residues of the ac-
tive site of myosin. The obtained data are of great 
interest with respect to further application of this 
nanosystem in the regulation of muscle contrac-
tion, especially for pathology condition. 
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ìàòåð³àë³â, çäàòíèõ âèÿâëÿòè ñïåöèô³÷íó 
á³îëîã³÷íó ä³þ, º âàæëèâîþ êîìïëåêñíîþ ïðîá-
ëåìîþ, ÿêà ïîòðåáóº âèêîðèñòàííÿ îñòàíí³õ 
äîñÿãíåíü á³îòåõíîëîã³¿. Ó ðîáîò³ äîñë³äæåíî 
âïëèâ íåìîäèô³êîâàíîãî âîäîðîç÷èííîãî ôó-
ëåðåíó C60 íà ÀÒÐàçíó àêòèâí³ñòü ³ ðåàêö³þ 
ñóïåðïðåöèï³òàö³¿ íàòóðàëüíîãî àêòîì³îçèíó 
ñêåëåòíèõ ì’ÿç³â êðîëÿ. Âñòàíîâëåíî äîçî-
çàëåæíèé õàðàêòåð éîãî ä³¿ íà Ìg2+,Ñà2+- òà 
Ê+-ATÐàçíó àêòèâí³ñòü òà ñóïåðïðåöèï³òàö³þ 
àêòîì³îçèíó. Öå â³äêðèâàº ïåðñïåêòèâè 
ðåãóëÿö³¿ ïðîöåñó ñêîðî÷åííÿ–ðîçñëàáëåííÿ 
ñêåëåòíèõ ì’ÿç³â çà äîïîìîãîþ äîñë³äæóâàíîãî 
Ñ60. 
Ê ë þ ÷ î â ³  ñ ë î â à: ôóëåðåí C60, 
àêòîì³îçèí ñêåëåòíèõ ì’ÿç³â, ÀÒÐàçíà 
àêòèâí³ñòü, ñóïåðïðåöèï³òàö³ÿ, àòîìíà ñèëîâà 
ì³êðîñêîï³ÿ, ìîëåêóëÿðíèé äîê³íã. 
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Èíñòèòóò õèìèè è áèîòåõíîëîãèè, ÔÐÃ
Ñîçäàíèå íîâûõ áèîñîâìåñòèìûõ íàíî-
ìàòåðèàëîâ, ñïîñîáíûõ ïðîÿâëÿòü ñïåöèôè÷å-
ñêîå áèîëîãè÷åñêîå äåéñòâèå, ÿâëÿåòñÿ âàæíîé 
êîìïëåêñíîé ïðîáëåìîé, êîòîðàÿ òðåáóåò èñ-
ïîëüçîâàíèÿ ïîñëåäíèõ äîñòèæåíèé áèîòåõíî-
ëîãèè. Â ðàáîòå èññëåäîâàíî âëèÿíèå íåìîäè-
ôèöèðîâàííîãî âîäîðàñòâîðèìîãî ôóëëåðåíà 
C60 íà ÀÒÐàçíóþ àêòèâíîñòü è ðåàêöèþ ñó-
ïåðïðåöèïèòàöèè íàòóðàëüíîãî àêòîìèîçèíà 
ñêåëåòíûõ ìûøö êðîëèêà. Óñòàíîâëåí äîçîçà-
âèñèìûé õàðàêòåð åãî äåéñòâèÿ íà Ìg2+,Ñà2+- 
è Ê+-ATÐàçíóþ àêòèâíîñòü è ñóïåðïðåöèïèòà-
öèþ àêòîìèîçèíà. Ýòî îòêðûâàåò ïåðñïåêòèâû 
ðåãóëÿöèè ïðîöåññà ñîêðàùåíèÿ–ðàññëàáëå-
íèÿ ñêåëåòíûõ ìûøö ñ ïîìîùüþ èññëåäîâàí-
íîãî ôóëëåðåíà Ñ60. 
Ê ë þ ÷ å â û å  ñ ë î â à: ôóëëåðåí C60, àê-
òîìèîçèí ñêåëåòíûõ ìûøö, ÀÒPàçíàÿ àêòèâ-
íîñòü, ñóïåðïðåöèïèòàöèÿ, àòîìíàÿ ñèëîâàÿ 
ìèêðîñêîïèÿ, ìîëåêóëÿðíûé äîêèíã. 
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